

Guangdi Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1845744/publications.pdf>

Version: 2024-02-01

50
papers

4,546
citations

218381

26
h-index

205818

48
g-index

50
all docs

50
docs citations

50
times ranked

9847
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). <i>Nature Reviews Drug Discovery</i> , 2020, 19, 149-150.	21.5	1,370
2	Approved Antiviral Drugs over the Past 50 Years. <i>Clinical Microbiology Reviews</i> , 2016, 29, 695-747.	5.7	1,049
3	Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. <i>Nature Human Behaviour</i> , 2020, 4, 856-865.	6.2	281
4	High-Throughput Analysis of Human Cytomegalovirus Genome Diversity Highlights the Widespread Occurrence of Gene-Disrupting Mutations and Pervasive Recombination. <i>Journal of Virology</i> , 2015, 89, 7673-7695.	1.5	148
5	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. <i>Antiviral Research</i> , 2017, 142, 83-122.	1.9	135
6	TRIM21 Promotes Innate Immune Response to RNA Viral Infection through Lys27-Linked Polyubiquitination of MAVS. <i>Journal of Virology</i> , 2018, 92, .	1.5	96
7	An integrated map of HIV genome-wide variation from a population perspective. <i>Retrovirology</i> , 2015, 12, 18.	0.9	90
8	Clinical significance of chemokine receptor antagonists. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 11-30.	1.5	90
9	A new ensemble coevolution system for detecting HIV-1 protein coevolution. <i>Biology Direct</i> , 2015, 10, 1.	1.9	78
10	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 1712-1724.	3.2	76
11	Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Clinical and Translational Immunology</i> , 2020, 9, e1182.	1.7	65
12	NLRX1 Mediates MAVS Degradation To Attenuate the Hepatitis C Virus-Induced Innate Immune Response through PCBP2. <i>Journal of Virology</i> , 2017, 91, .	1.5	62
13	HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, 679-731.	2.9	61
14	Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5. <i>Journal of Virology</i> , 2018, 92, .	1.5	60
15	Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. <i>Viruses</i> , 2015, 7, 5018-5039.	1.5	59
16	Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 813-829.	1.5	57
17	Functional conservation of HIV-1 Gag: implications for rational drug design. <i>Retrovirology</i> , 2013, 10, 126.	0.9	56
18	DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. <i>Nature Communications</i> , 2020, 11, 4467.	5.8	51

#	ARTICLE	IF	CITATIONS
19	Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. <i>Aging</i> , 2021, 13, 27-60.	1.4	49
20	The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/ β -catenin signaling pathway. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1163-1179.	4.8	40
21	APPLs: More than just adiponectin receptor binding proteins. <i>Cellular Signalling</i> , 2017, 32, 76-84.	1.7	39
22	Rheb Inhibits Beiging of White Adipose Tissue via PDE4D5-Dependent Downregulation of the cAMP-PKA Signaling Pathway. <i>Diabetes</i> , 2017, 66, 1198-1213.	0.3	39
23	Obesity-Associated miR-199a/214 Cluster Inhibits Adipose Browning via PRDM16-PCG-1 β Transcriptional Network. <i>Diabetes</i> , 2018, 67, 2585-2600.	0.3	39
24	Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic. <i>PLoS ONE</i> , 2014, 9, e101738.	1.1	36
25	Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. <i>Reviews in Medical Virology</i> , 2016, 26, 408-434.	3.9	34
26	Approved HIV reverse transcriptase inhibitors in the past decade. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1567-1590.	5.7	31
27	Trends in the disease burden of HBV and HCV infection in China from 1990-2019. <i>International Journal of Infectious Diseases</i> , 2022, 122, 476-485.	1.5	31
28	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. <i>Hepatology International</i> , 2020, 14, 212-224.	1.9	26
29	Clinical characteristics of older and younger patients infected with SARS-CoV-2. <i>Aging</i> , 2020, 12, 11296-11305.	1.4	25
30	A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. <i>Antiviral Research</i> , 2014, 112, 91-102.	1.9	24
31	Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. <i>Immunity and Ageing</i> , 2022, 19, 12.	1.8	23
32	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. <i>Biomedicines</i> , 2021, 9, 412.	1.4	22
33	Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. <i>Molecules</i> , 2021, 26, 923.	1.7	21
34	The IL-21-CTET2-CAIM2-MAF pathway drives the T follicular helper cell response in lupus-like disease. <i>Clinical and Translational Medicine</i> , 2022, 12, e781.	1.7	20
35	Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2759-2774.	2.0	19
36	Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. <i>Virus Evolution</i> , 2016, 2, vew024.	2.2	17

#	ARTICLE	IF	CITATIONS
37	Antifungal activity of spider venom-derived peptide lycosin-I against <i>Candida tropicalis</i> . <i>Microbiological Research</i> , 2018, 216, 120-128.	2.5	17
38	DsbA-L interacts with VDAC1 in mitochondrion-mediated tubular cell apoptosis and contributes to the progression of acute kidney disease. <i>EBioMedicine</i> , 2022, 76, 103859.	2.7	13
39	Drivers of HIV-1 transmission: The Portuguese case. <i>PLoS ONE</i> , 2019, 14, e0218226.	1.1	12
40	HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. <i>Retrovirology</i> , 2014, 11, 79.	0.9	11
41	The relationships among verbal ability, executive function, and theory of mind in young children with cochlear implants. <i>International Journal of Audiology</i> , 2018, 57, 881-888.	0.9	10
42	Molecular epidemiology, phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia: Predominance of genotype D1. <i>Infection, Genetics and Evolution</i> , 2020, 77, 104051.	1.0	10
43	C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. <i>Oncogene</i> , 2020, 39, 3354-3366.	2.6	10
44	Antiviral Classification. , 2021, , 121-130.		10
45	Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. <i>Biochemical Pharmacology</i> , 2021, 185, 114485.	2.0	9
46	Global Burden of Nutritional Deficiencies among Children under 5 Years of Age from 2010 to 2019. <i>Nutrients</i> , 2022, 14, 2685.	1.7	8
47	A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951â€“2021). <i>Medicinal Research Reviews</i> , 2021, , .	5.0	6
48	Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits. <i>Virology</i> , 2014, 456-457, 310-318.	1.1	5
49	Molecular mechanisms underlying hepatitis C virus infection-related diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154802.	1.5	5
50	Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1